Core Insights - Zhendemedical is a leading company in the medical dressing industry in China, established in 1994 and listed on the Shanghai Stock Exchange in 2018, with a comprehensive supply chain advantage and products sold in multiple countries and regions [1] Financial Performance - For Q3 2025, Zhendemedical reported revenue of 3.184 billion yuan, ranking 6th out of 50 in the industry, surpassing the industry average of 1.379 billion yuan and the median of 755.0 million yuan [2] - The net profit for the same period was 211 million yuan, ranking 17th in the industry, above the industry average of 183 million yuan and the median of 75.88 million yuan [2] Financial Ratios - As of Q3 2025, Zhendemedical's debt-to-asset ratio was 28.78%, higher than the previous year's 25.86% and above the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 33.93%, down from 34.84% year-on-year but still above the industry average of 48.78% [3] Executive Compensation - The chairman, Lu Jianguo, received a salary of 1.7762 million yuan in 2024, an increase of 170,900 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 4.06% to 23,600, with an average holding of 11,300 circulating A-shares, a decrease of 3.90% [5] - The top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 190,000 shares [5] Business Highlights - Zhendemedical's revenue from surgical infection control, stoma care, and modern wound care showed growth, with domestic hospital operations covering nearly 9,200 hospitals [5] - The overseas business also performed well, with a year-on-year revenue increase of 13% [5] - According to Huachuang Securities, the company is expected to achieve net profits of 400 million, 450 million, and 530 million yuan from 2025 to 2027 [5] - Xinda Securities noted that overseas capacity ramp-up is driving revenue growth, with significant growth in surgical infection control and modern wound dressings [6]

上证指数本月上涨1.85%，230股股价创历史新高。 本月可交易A股中，股价上涨的有3051只，占比56.06%，下跌的有2364只，占比43.44%。 证券时报·数据宝统计显示，不含近一年上市的次新股，共有230股本月股价创出历史新高，按所属板块 看，主板有114只，创业板有55只，科创板有50只，北交所有11只。从行业属性来看，电子、机械设 备、有色金属行业创新高的个股较为集中，分别有58只、34只、29只个股出现名单中。 市场表现来看，本月创历史新高股平均上涨10.24%，涨幅最大的是振德医疗，本月上涨103.60%，本月 换手率123.42%，涨幅居前的还有时空科技、利通科技、鼎泰高科等，本月股价下跌的有73只，分别是 联合化学、正帆科技、泰凌微等，跌幅分别为24.71%、24.26%、22.60%。股价方面，创新高股平均收 盘价为72.30元，其中，股价超百元的有46只，50元~100元的有53只，收盘股价最高的是国盾量子，收 盘价为579.80元，本月上涨65.19%，其次是源杰科技、中际旭创，收盘价分别为508.07元、473.01元。 以最新收盘价计算，创新高股平均A股总市值700.59亿元， ...

Market Overview - The A-share market showed a mixed performance in October, with the Shanghai Composite Index rising by 1.85%, marking its longest monthly gain streak since 2014, while the Shenzhen Component Index and the ChiNext Index both declined by 1.1% and 1.56% respectively [2][3] - The average stock price in A-shares fell by 0.64% to 26.5 yuan, and the total trading volume in the Shanghai and Shenzhen markets reached 36.4 trillion yuan, with an average daily trading volume of 2.14 trillion yuan [2] Sector Performance - The coal industry led the sector performance in October with a monthly increase of 10.02%, rebounding after a prolonged slump, while the steel and non-ferrous metals sectors also performed well with increases of 5.16% and 5.00% respectively [4][6] - The overall performance of large-cap and small-cap stocks was relatively balanced, with the CSI 100 index down by 0.17% and the CSI 500 index down by 1.1% [3][4] Investment Strategies - Analysts suggest a "dumbbell" strategy focusing on technology growth and high dividend stocks, emphasizing sectors such as autonomous technology, chips, and high-end manufacturing [7][8] - The market outlook for November remains optimistic, with expectations of a "slow bull" market driven by policy support and improved external conditions [7][9]

1、行情 指数集体回落，但整体涨多跌少的一天。 题材方面，创新药板块迎来大幅反弹，联环药业、三生国建（20CM）、昂利康、舒泰神（20CM）、众生药业、海思科等集体涨停，泽璟制 药、益方生物、迈威生物、荣昌生物、苑东生物、海特生物、广生堂、百利天恒等涨超10%； 传媒板块局部发力，荣信文化、山东出版、粤传媒、福石控股（20CM）先后涨停，蓝色光标、中文在线、视觉中国、掌阅科技等集体大涨； 两岸概念迎来局部大反弹，平潭发展7天6板，合富中国、瑞尔特4连板，海峡创新（20CM）、福建金森、福龙马等涨停，漳州发展、中国武 夷、榕基软件等走强； 此外，AI智能体、海南自贸港、超聚变概念等有局部强势表现，科技股集体大跌。 截至收盘，沪指、深成指、创业板指分别收跌0.81%、1.14%、2.31%，市场超3700股上涨，1500余股下跌，两室成交量维持在2.3万亿。 十月的交易正式结束， 沪指、北证50的月涨幅分别为1.85%、3.54%，深成指、创业板指、科创50分别收跌1.1%、1.56%、5.33%。 因为在大家的心中，分析师发出来的东西肯定是可信度高的，甚至会认为有券商背书之类的，所以会更倾向于信任。 之前行情火 ...

证券之星消息，10月31日医疗器械板块较上一交易日上涨1.13%，采纳股份领涨。当日上证指数报收于 3954.79，下跌0.81%。深证成指报收于13378.21，下跌1.14%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301122 | 采纳股份 | 30.38 | 19.98% | 9.10万 | | 2.59亿 | | 688236 | 春立医疗 | 28.88 | 14.47% | 8.42万 | | 2.35亿 | | 603301 | 振德医疗 | 95.00 | 9.07% | 21.19万 | | 19.51亿 | | 300642 | 透景生命 | 24.08 | 8.81% | 1 23.65万 | | 5.65亿 | | 688068 | 热景生物 | 160.00 | 8.70% | 6.30万 | | 9.81亿 | | 688298 | 东方生物 | 26.65 | 7.24% | 8.61万 | | 2.27亿 | ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-040 振德医疗用品股份有限公司 关于拟回购注销第一期员工持股计划部分股份 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司(以下简称:"公司")于 2025 年 7 月 23 日、8 月 11 日分别召开了第三届董事会第二十二次会议、第三届 监事会第十九次会议及 2025 年第一次临时股东大会，审议通过了《关 于回购公司第一期员工持股计划未解锁股份的议案》、《关于变更部分 回购股份用途并注销的议案》及《关于取消监事会、变更公司注册资 本、增加经营范围暨修订<公司章程>并办理工商变更登记的议案》， 拟将公司第一期员工持股计划（以下简称"本员工持股计划"）未能 解锁的 615,667 股公司股份予以回购注销。现将有关事项说明如下： 一、已履行的相关审批程序和信息披露情况 公司分别于 2021 年 5 月 24 日、2021 年 6 月 15 日召开第二届董 事会第十七次会议和 2021 年第二次临时股东大会，审议通过了《关 于< ...

振德医疗股价创出历史新高，截至9:48，该股上涨3.02%，股价报88.99元，成交量423.43万股，成交金 额3.74亿元，换手率1.59%，该股最新A股总市值达237.11亿元，该股A股流通市值237.11亿元。 证券时报·数据宝统计显示，振德医疗所属的医药生物行业，目前整体跌幅为0.86%，行业内，目前股价 上涨的有135只，涨停的有合富中国、奥美医疗等3只。股价下跌的有345只，跌幅居前的有翰宇药业、 药明康德、康芝药业等，跌幅分别为8.97%、7.71%、6.94%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 两融数据显示，该股最新(10月29日)两融余额为10.89亿元，其中，融资余额为10.88亿元，近10日增加 2.16亿元，环比增长24.71%。 公司发布的三季报数据显示，前三季度公司共实现营业收入31.84亿元，同比增长1.88%，实现净利润 2.03亿元，同比下降33.91%，基本每股收益为0.7600元，加权平均净资产收益率3.57%。 ...

Company Performance - Zhendemedical's stock price reached a historical high, increasing by 3.02% to 88.99 yuan, with a trading volume of 4.2343 million shares and a transaction value of 374 million yuan, resulting in a turnover rate of 1.59% [2] - The latest total market capitalization of Zhendemedical in A-shares is 23.711 billion yuan, with the circulating market capitalization also at 23.711 billion yuan [2] - The company's Q3 report indicates a total operating revenue of 3.184 billion yuan for the first three quarters, representing a year-on-year growth of 1.88%, while net profit decreased by 33.91% to 203 million yuan, with basic earnings per share at 0.7600 yuan and a weighted average return on equity of 3.57% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which Zhendemedical belongs, experienced an overall decline of 0.86%, with 135 stocks rising and 3 stocks hitting the daily limit, including HeFu China and Aomei Medical [2] - Conversely, 345 stocks in the industry saw declines, with the largest drops recorded by Hanyu Pharmaceutical, WuXi AppTec, and Kangzhi Pharmaceutical, with declines of 8.97%, 7.71%, and 6.94% respectively [2] Margin Trading Data - As of October 29, the latest margin trading balance for Zhendemedical is 1.089 billion yuan, with a financing balance of 1.088 billion yuan, reflecting an increase of 216 million yuan over the past 10 days, which is a 24.71% increase [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603301 证券简称：振德医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 □适用 √不适用 （三） 主要会计数据、 ...

每经头条（nbdtoutiao）——"十五五"规划建议的18个新提法，释放了哪些重要信号？ （记者 张明双） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，振德医疗（SH 603301，收盘价：86.38元）10月29日晚间发布三季度业绩公告称，2025年 前三季度营收约31.84亿元，同比增加1.88%；归属于上市公司股东的净利润约2.03亿元，同比减少 33.91%；基本每股收益0.76元，同比减少33.91%。 截至发稿，振德医疗市值为230亿元。 每日经济新闻 ...